➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Johnson and Johnson
Moodys
Boehringer Ingelheim
Dow

Last Updated: May 28, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR XADAGO

» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for XADAGO

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02495831 Drug Interaction Study of Safinamide and a BCRP Substrate, Diclofenac, Concomitantly Administered to Healthy Volunteers Completed Cross Research S.A. Phase 1 2015-05-01 To evaluate if a single dose of safinamide 200 mg has an effect on the pharmacokinetics of diclofenamic acid, concomitantly administered as a single 50 mg diclofenac sodium dose, with respect to 50 mg diclofenac sodium administered alone.
NCT02495831 Drug Interaction Study of Safinamide and a BCRP Substrate, Diclofenac, Concomitantly Administered to Healthy Volunteers Completed Zambon SpA Phase 1 2015-05-01 To evaluate if a single dose of safinamide 200 mg has an effect on the pharmacokinetics of diclofenamic acid, concomitantly administered as a single 50 mg diclofenac sodium dose, with respect to 50 mg diclofenac sodium administered alone.
NCT03216304 Safinamide Steady State Interaction With Rosuvastatine Recruiting Zambon SpA Phase 1 2017-05-22 To evaluate if safinamide at the steady state, obtained after multiple 100 mg once a day administrations, has an effect on the pharmacokinetics of rosuvastatin, concomitantly administered as a single 20 mg dose, with respect to the pharmacokinetics of 20 mg rosuvastatin administered alone.
NCT03216304 Safinamide Steady State Interaction With Rosuvastatine Recruiting Cross Research S.A. Phase 1 2017-05-22 To evaluate if safinamide at the steady state, obtained after multiple 100 mg once a day administrations, has an effect on the pharmacokinetics of rosuvastatin, concomitantly administered as a single 20 mg dose, with respect to the pharmacokinetics of 20 mg rosuvastatin administered alone.
NCT03843944 Overnight Switch From Rasagiline To Safinamide Recruiting IRCCS San Raffaele Phase 4 2018-05-01 Rasagiline label report the indication to wait at least 14 days between discontinuation of rasagiline and initiation of another MAO inhibitor. This results in a major inconvenience for Parkinsonian patients (PD) due to their clinical worsening. Safinamide is a reversible MAO-B inhibitor, characterized by a good safety profile. In clinical practice safinamide is often introduced instead of rasagiline following an overnight switch. The aim of this study is to explore the safety and tolerability of the immediate switch from rasagiline (irreversible MAO-B inhibitor) to safinamide, with the expectation that there will be no adverse events or increased risk of hypertensive crisis for patients with PD or signs of serotonin syndrome
NCT03968744 Effect of Safinamide on Sleep Quality in Patients With Parkinson's Disease Recruiting Clinical Trial Unit Ente Ospedaliero Cantonale Phase 4 2019-02-18 Patients suffering of Parkinson's Disease will be treated with 50 mg/day of Safinamide per os for 2 weeks (escalation phase). Then, safinamide will be increased up to 100 mg/day and, if tolerated, the treatment will be taken for 10 more weeks (maintenance phase). Total treatment 12 weeks.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for XADAGO

Condition Name

Condition Name for XADAGO
Intervention Trials
Healthy 2
Parkinson Disease 1
Idiopathic Parkinson's Disease (at Later Stage) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for XADAGO
Intervention Trials
Parkinson Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for XADAGO

Trials by Country

Trials by Country for XADAGO
Location Trials
Switzerland 3
Italy 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for XADAGO

Clinical Trial Phase

Clinical Trial Phase for XADAGO
Clinical Trial Phase Trials
Phase 4 2
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for XADAGO
Clinical Trial Phase Trials
Recruiting 3
Completed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for XADAGO

Sponsor Name

Sponsor Name for XADAGO
Sponsor Trials
Zambon SpA 2
Cross Research S.A. 2
Clinical Trial Unit Ente Ospedaliero Cantonale 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for XADAGO
Sponsor Trials
Industry 4
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Express Scripts
McKinsey
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.